Skip to main content

Table 1 Biosimilars available in ambulatory care in Belgium (May 2021) [10]

From: Knowledge and perception of biosimilars in ambulatory care: a survey among Belgian community pharmacists and physicians

INN Product type Net 2019 expenditure [26] Reference product Biosimilar Reimbursement date biosimilar** [27]
Adalimumab* TNF inhibitor 95.207.248 Humira® Amgevita® 1/10/2018
Hulio® 1/1/2019
Hyrimoz® 1/1/2019
Idacio® 1/10/2019
Imraldi® 1/10/2018
Enoxaparin* LMWH 22.446.229 Clexane® Ghemaxan® 1/1/2021
Etanercept* TNF inhibitor 45.197.777 Enbrel® Benepali® 1/09/2016
Erelzi® 1/7/2019
Nepexto® 1/2/2021
Filgrastim G-CSF NPA Neupogen® Accofil® 1/6/2016
Nivestim® 1/3/2014
Tevagrastim® 1/2/2010
Follitropin alfa FSH NPA Gonal-F® Bemfola® NA
Ovaleap® NA
Insulin glargine* Long-acting insulin analogue 30.344.794 Lantus® Abasaglar® 1/6/2016
Somatropin Growth hormone NPA Genotropin® Omnitrope® 1/4/2014
  1. G-CSF granulocyte colony-stimulating factor, INN international non-proprietary name, LMWH low molecular weight heparin, NPA not publicly available, NA not applicable, non-reimbursed medicines, FSH follicle-stimulating hormone, TNF tumor necrosis factor
  2. *Biologicals that are part of the top 25 medicine expenditures in the Belgian ambulatory sector. Insulin aspart is also part of this list (reference product: NovoRapid®, net 2019 expenditure: 22.229.748) and has an authorized biosimilar: Insulin aspart Sanofi®. Insulin aspart Sanofi® has, however, not (yet) been launched in Belgium [26]. Also the EU-approved biosimilars of teriparatide (reference product: Forsteo®, EU-approved biosimilars: Movymia®, Terrosa®, Livogiva®, Qutavina®) and insulin lispro (reference product: Humalog®, EU-approved biosimilar: Insulin Lispro Sanofi®) are not (yet) available on the market in Belgium [6, 26, 28]
  3. **Reimbursement date of the first available product package